Chronic calcineurin inhibitor nephrotoxicity-lest we forget

American Journal of Transplantation

Volumn 11, Issue 4, 2011, Pages 693-697

  Chapman, J R ^a  

^a WESTMEAD HOSPITAL   (Australia)

Author keywords

Azathioprine; cyclosporine; everolimus; sirolimus; tacrolimus

Indexed keywords

ANTIBODY; AZATHIOPRINE; CALCINEURIN INHIBITOR; CYCLOSPORIN; PREDNISOLONE;

ALLOIMMUNITY; CHRONIC DISEASE; DOSE RESPONSE; FOLLOW UP; GLOMERULOSCLEROSIS; GRAFT FAILURE; GRAFT SURVIVAL; HUMAN; HYALINE DEGENERATION; HYPERTENSION; KIDNEY ALLOGRAFT; KIDNEY BIOPSY; KIDNEY FIBROSIS; KIDNEY FUNCTION; NEPHROTOXICITY; NONHUMAN; OUTCOME ASSESSMENT; PRIORITY JOURNAL; RECURRENT DISEASE; REVIEW; RISK FACTOR; TREATMENT OUTCOME;

CALCINEURIN; CHRONIC DISEASE; HUMANS; IMMUNOSUPPRESSIVE AGENTS; KIDNEY DISEASES; RISK FACTORS;

EID: 79953250784     PISSN: 16006135     EISSN: 16006143     Source Type: Journal    
DOI: 10.1111/j.1600-6143.2011.03504.x     Document Type: Review

References (35)

1. Calne RY, White DJ, Thiru S, et al,. Cyclosporin A in patients receiving renal allografts from cadaver donors. Lancet 1978; 2: 1323-1327. (Pubitemid 9078430)
2. Ryffel B,. Experimental toxicological studies with cyclosporin A. In:, White DJG, ed. Cyclosporin A, Amsterdam: Elsevier Biomedical Press, 1982: 45-75.
3. Chapman JR, Griffiths D, Harding NG, Morris PJ,. Reversibility of cyclosporin nephrotoxicity after three months' treatment. Lancet 1985; 1: 128-130. (Pubitemid 15152468)
4. Henny FC, Kleinbloesem CH, Moolenaar AJ, Paul LC, Breimer DD, van Es LA,. Pharmacokinetics and nephrotioxicity of cyclosporine in renal transplant recipients. Transplantation 1985; 40: 261-265. (Pubitemid 15023184)
5. Murray BM, Paller MS, Ferris TF,. Effect of cyclosporine administration on renal haemodynamics in conscious rats. Kidney Int 1987; 32: 19-25.
6. Myers BD, Ross J, Newton L, Luetscher J, Perlroth M,. Cyclosporine-associated chronic nephropathy. N Engl J Med 1984; 311: 699-705. (Pubitemid 14074555)
7. English J, Evan A, Houghton DC, Bennett WM,. Cyclosporine-induced acute renal dysfunction in the rat. Evidence of arteriolar vasoconstriction with preservation of tubular function. Transplantation 1987; 44: 135-141.
8. D'Ardenne AJ, Dunnill MS, Thompson JF, McWhinnie DL, Wood RFM, Morris PJ,. Cyclosporine and renal graft histology. J Clin Pathol 1986; 39: 145-151.
9. Tiller DJ, Hall BM, Horvarth JS, Duggin GG, Thompson JF, Sheil AG,. Gout and hyperuricaemia in patients on cyclosporin and diuretics. Lancet 1985; 1: 453. (Pubitemid 15173149)
10. Naesen M, Kuypers DR, Sarwal M,. Calcineurin inhibitor nephrotoxicity. Clin J Am Soc Nephrol 2009; 4: 481-508.
11. Bennett WM, Houghton DC, Buss WC,. Cyclosporine-induced renal dysfunction: Correlations between cellular events and whole kidney function. J Am Soc Nephrol 1991; 1: 1212-1219.
12. Perico N, Ruggenenti P, Gaspari F, et al,. Daily renal hypoperfusion induced by cyclosporine in patients with renal transplantation. Transplantation 1992; 54: 56-60.
13. Feutren G, Mihatsch MJ,. Risk factors for cyclosporine induced nephropthay in patients with autoimmune diseases. N Engl J Med 1992; 326: 1654-1660.
14. Solez K, Axelsen RA, Benediktsson H, et al,. International standardization of criteria for the histologic diagnosis of renal allograft rejection: The Banff working classification of kidney transplant pathology. Kidney Int 1993; 44: 411-422. (Pubitemid 23228698)
15. Ojo AO, Held PJ, Port FK, et al,. Chronic renal failure after transplantation of a nonrenal organ. N Engl J Med 2003; 349: 931-940. (Pubitemid 37064766)
16. Schwarz A, Haller H, Schmitt R, et al,. Biopsy diagnosed renal disease in patients after transplantation of other organs and tissues. Am J Transplant 2010; 10: 2017-2025.
17. Morozumi K, Takeda A, Uchida K, Mihatsch MJ,. Cyclosporine nephrotoxicity: How does it affect renal allograft function and transplant morphology. Transplant Proc 2004; 36 (2S): 251S-256S. (Pubitemid 38373872)
18. Bakker RC, Scholten EM, de Fijter JW, Paul LC,. Chronic cyclosporine nephrotoxicity in renal transplantation. Transplant Rev 2004; 18: 54-64. (Pubitemid 38744804)
19. Mannon RB, Matas AJ, Grande J, et al,. Inflammation in areas of tubular atrophy in kidney allograft biopsies: A potent predictor of allograft failure. Am J Transplant 2010; 10: 2066-2073.
20. Matas AJ, Leduc R, Rush D, et al,. Histopathologic clusters differentiate subgroups within the nonspecific diagnoses of CAN or CR: Preliminary data from the DeKAF study. Am J Transplant 2010; 10: 315-323.
21. Stegall MD, Park WD, Larson TS, et al,. The histology of solitary renal allografts at 1 and 5 years after transplantation. Am J Transplant 2010; Epub ahead of print. doi
22. Nankivell BJ, Burrows RJ, Fung CL, O'Connell PJ, Allen RDM, Chapman JR,. The natural history of chronic allograft nephropathy. N Engl J Med 2003; 349: 2326-2333. (Pubitemid 37509740)
23. Nankivell BJ, Chapman JR, Bonovas G, Gruenewald SM,. Oral Cyclosporine but not Tacrolimus reduces renal transplant blood flow. Transplantation 2004; 77: 1457-1459. (Pubitemid 38668444)
24. Nankivell BJ, Borrows RJ, Fung CL, O'Connell PJ, Allen RD, Chapman JR,. Evolution and pathophysiology of renal-transplant glomerulosclerosis. Transplantation 2004; 78: 461-468.
25. Nankivell BJ, Burrowws RJ, Fung CL, O'Connell PJ, Chapman JR, Allen RDM,. Calcineurin Inhibitor nephrotoxicity: Longitudinal assessment by protocol histology. Transplantation 2004; 78: 557-565. (Pubitemid 39097102)
26. Wavamunno MD, O'Connell PJ, Vitalone M, et al,. Transplant glomerulopathy: Ultrastructural abnormalities occur early in longitudinal analysis of protocol biopsies. Am J Transplant 2007; 7: 2757-2768. (Pubitemid 350045771)
27. Canaud G, Martinez F, Noël LH, Mamzer MF, Niaudet P, Legendre C,. Therapeutic approach to focal and segmental glomerulosclerosis recurrence in kidney transplant recipients. Transplant Rev (Orlando) 2010; 24: 121-128.
28. Rohan J, Konvalinka A, Tobar A, et al,. Determinants of long-term graft outcome in transplant glomerulopathy. Transplantation 2010; 90: 757-764.
29. Rush D,. Protocol transplant biopsies: An underutilized tool in kidney transplantation. Clin J Am Soc Nephrol 2006; 1: 138-143.
30. Kasiske BL, Chakkera HA, Louis TA, Ma JZ,. A meta-analysis of immunosuppression withdrawal trials in renal transplantation. J Am Soc Nephrol 2000; 11: 1910-1917.
31. Gallagher M, Jardine M, Perkovic V, et al,. Cyclosporine withdrawal improves long-term graft survival in renal transplantation. Transplantation 2009; 87: 1877-1883.
32. Ponticelli C, Tarantino F, Quarto di Palo F, et al,. Randomized study with cyclosporine in kidney transplantation: 10 year follow-up. J Am Soc Nephrol 1996; 7: 792-797. (Pubitemid 27466014)
33. Mulay AV, Cockfield S, Stryker R, Fergusson D, Knoll GA,. Conversion from calcineurin inhibitors to sirolimus for chronic renal allograft dysfunction: A systematic review of the evidence. Transplantation 2006; 82: 1153-1162. (Pubitemid 44748017)
34. Webster AC, Lee VW, Chapman JR, Craig JC,. Target of rapamycin inhibitors (sirolimus and everolimus) for primary immunosuppression of kidney transplant recipients: A systematic review and meta-analysis of randomized trials. Transplantation 2006; 81: 1234-1248.
35. Chapman JR, O'Connell PJ, Nankivell BJ,. Chronic renal allograft dysfunction. J Am Soc Nephrol 2005; 16: 3015-3026. (Pubitemid 44743499)